echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca's CLL drug Calquence is approved by NICE in the UK

    AstraZeneca's CLL drug Calquence is approved by NICE in the UK

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationFan Dongdong

    A few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).


    According to the draft recommendation guidelines issued by the British regulatory agency, the drug has been approved in December last year for the treatment of CLL patients with 17p deletion or TP53 mutation, or fludarabine combined with cyclophosphamide and rituximab (FCR), and bendumustine combined with rituximab (BR).


    Calquence's NICE recommendation in the United Kingdom will provide this type of patient with a new treatment option other than chemotherapy, which is especially helpful during the COVID-19 pandemic.


    In November last year, the European Medicines Agency (EMA) approved Calquence as a monotherapy or in combination with Roche Gazyvaro (obinutuzumab) for previously untreated and relapsed or refractory CLL patients.


    Reference source:

    1.


    2.


    3.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.